状细胞衍生生物标志物评分预测慢性肝病的诊断和预后
Sergi Guixé-Muntet1, Anabel Fernández-Iglesias1, David Lopez2
1Liver Vascular Biology Research Group, IDIBAPS Biomedical Research Institute, Hospital Clínic de Barcelona, CIBEREHD, Barcelona, Spain.
BMC medicine
|March 1, 2026
概括
来自状细胞的新生物标志物准确地诊断和预测慢性肝病 (CLD) 的进展和回归. 这些得分可以从现有的肝脏活检中测量,为患者分层和监测提供了一个有前途的工具.
科学领域:
- 肝病学和细胞生物学.
- 发现生物标志物的发现.
- 慢性肝病 (CLD) 的研究.
背景情况:
- 鼻状细胞是慢性肝病 (CLD) 进展的关键驱动因素.
- 目前的生物标志物不能充分反映状细胞状态.
- 需要新的生物标志物用于CLD诊断和预后.
研究的目的:
- 开发用于CLD的状细胞特异性生物标志物.
- 评估这些生物标志物的诊断和预后能力.
主要方法:
- 单细胞RNA测序以识别细胞类型特定的特征.
- 集成的签名进入内皮细胞,介质细胞和巨细胞的阴侧分数.
- 在四个独立队列 (n=1116) 中使用肝活检样本验证得分.
主要成果:
- 在晚期的CLD中,鼻状点数升高,与脱补偿,门性高血压和肝功能受损相关.
- 评分预测了纤维化进展/回归和脱补偿.
- 评分显示了各种临床终点的高诊断准确性 (AUROC 0.7880.971).
结论:
- 状细胞衍生得分反映了CLD进展和回归途径.
- 评分可以从现有的活检材料中测量,确保全球可行性.
- 评分显示,在患者分层和监测中临床实施具有前景.
更多相关视频
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
2.1K
08:56Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
54.9K
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
244
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
887
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
887